Unify Markov model for Rational Design and Synthesis of More Safe Drugs. Predicting Multiple Drugs Side Effects

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Química Orgánicagl
dc.contributor.authorCruz Monteagudo, Maykel
dc.contributor.authorGonzález Díaz, Humberto
dc.contributor.authorCabrera Pérez, Miguel A.
dc.contributor.authorMolina Ruiz, Reinaldo
dc.contributor.authorPérez Castillo, Yunierkis
dc.date.accessioned2021-08-19T12:45:44Z
dc.date.available2021-08-19T12:45:44Z
dc.date.issued2005
dc.descriptionThe 9th International Electronic Conference on Synthetic Organic Chemistry session Computational Chemistrygl
dc.description.abstractMost of present mathematical models for rational design and synthesis of new drugs consider just the molecular structure. In the present article we pretend extending the use of Markov Chain models to define novel molecular descriptors, which consider in addition other parameters like target site or biological effect. Specifically, this model takes into consideration not only the molecular structure but the specific biological system the drug affects too. Herein, it is developed a general Markov model that describes 19 different drugs side effects grouped in 8 affected biological systems for 178 drugs, being 270 cases finally. The data was processed by Linear Discriminant Analysis (LDA) classifying drugs according to their specific side effects, forward stepwise was fixed as strategy for variables selection. The average percentage of good classification and number of compounds used in the training/predicting sets were 100/95.8% for endocrine manifestations(18 out of 18)/(13 out of 14); 90.5/92.3% for gastrointestinal manifestations (38 out of 42)/(30 out of 32); 88.5/86.5% for systemic phenomena (23 out of 26)/(17 out of 20); 81.8/77.3% for neurological manifestations (27 out of 33)/(19 out of 25); 81.6/86.2% for dermal manifestations (31 out of 38)/(25 out of 29); 78.4/85.1% for cardiovascular manifestation (29 out of 37)/(24 out of 28); 77.1/75.7% for breathing manifestations (27 out of 35)/(20 out of 26) and 75.6/75% for psychiatric manifestations (31 out of 41)/(23 out of 31). Additionally a Back-Projection Analysis (BPA) was carried out for two ulcerogenic drugs to prove in structural terms the physic interpretation of the models obtained. This article develops a model that encompasses a large number of drugs side effects grouped in specifics biological systems using stochastic absolute probabilities of interaction (Apk (j)) by the first time.gl
dc.identifier.citationProceedings of the 9th International Electronic Conference on Synthetic Organic Chemistry, 1–30 November 2005, MDPI: Basel, Switzerland, doi:10.3390/ecsoc-9-01658gl
dc.identifier.doi10.3390/ecsoc-9-01658
dc.identifier.isbn3-906980-16-2
dc.identifier.urihttp://hdl.handle.net/10347/26893
dc.language.isoenggl
dc.publisherMDPIgl
dc.relation.ispartofseriesElectronic Conference on Synthetic Organic Chemistry;9
dc.relation.publisherversionhttps://doi.org/10.3390/ecsoc-9-01658gl
dc.rights© 2005 The author(s). Published by MDPI, Basel, Switzerland. Open Accessgl
dc.rights.accessRightsopen accessgl
dc.titleUnify Markov model for Rational Design and Synthesis of More Safe Drugs. Predicting Multiple Drugs Side Effectsgl
dc.typebook partgl
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2005_ecsoc9_cruz_unify.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format
Description: